Europe’s Regulatory Shake-Up Raises Concerns for Advanced Therapies

Published on Cytotherapy

A new perspective warns that restructuring advanced therapy oversight within the European Medicines Agency could weaken specialized expertise at a time when Europe already trails North America and Asia-Pacific in CGT clinical trials. The authors urge policymakers to maintain access to regulatory guidance that developers need to bring therapies to patients.

👉 Read the full article: Regulatory shake-up in Europe: Who will champion advanced therapy expertise?

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.